Skip to main content
XTNT logo

Xtant Medical Holdings, Inc. (XTNT) Stock Price & Analysis

Xtant Medical Holdings, Inc. (XTNT) — MoonshotScore 25/100 (Weak band), calculated Nov 22, 2026. Price $0.21 (-2.82%), as of the Nov 20, 2026 trading session; market cap $29.5M.

Educational signal · not a buy or sell recommendation · How to read this

$0.21 −$0.0061 (-2.82%) Market Cap $29.5M

Xtant Medical Holdings, Inc. · XTNT

Xtant Medical Holdings, Inc. specializes in regenerative medicine products and medical devices for orthopedic and neurological surgeons. The company is headquartered in Belgrade, Montana, and operates both domestically and internationally.

Price as of Nov 20, 2026

Key Statistics

25 of 100

MoonshotScore v2 · Xtant Medical Holdings (XTNT)

Weak
Business Quality Solid (63)
Financial Safety Fragile (17)
Valuation Fair (74)
Growth Durability Fading (20)
Momentum Slipping (31)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and stalling growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $23M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z -3.27 · Piotroski F 2

Holding back: balance-sheet strain, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for XTNT (58 recorded, newest six shown)
RecordedScoreBand
26Weak
26Weak
26Weak
24Weak
24Weak
24Weak

The score moved from 24 in the stored Nov 21, 2026 snapshot to 25 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Momentum +3. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.21
Change on the day-2.82%
52-week range$0.17 – $0.84
Market capitalisation$29.5M—
Price / earnings (trailing)35.23
Shares traded on the day257.1K

Price & events

Other perspectives

Council score for Xtant Medical Holdings (XTNT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Moderate
Growth Durability Weak
Momentum Weak

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Negative
Gross Margin Moderate

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Xtant Medical Holdings (XTNT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Xtant Medical Holdings, Inc. (XTNT) is the company analyzed here. It employs 151 people and is led by Sean E. Browne. In Q2 FY2026 it reported revenue of $23M and net income of -$9M. The market values it at $29.5M.

2 · Latest results

What do the latest results show for Xtant Medical Holdings (XTNT)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $23M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$23M-$9M-$0.07 (diluted)
Q1 FY2026$21M-$3M-$0.02 (diluted)
Q4 FY2025$32M$57,000$0.0004 (diluted)
Q3 FY2025$33M$1M$0.01 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Xtant Medical Holdings (XTNT)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -3.27 · Piotroski F 2. Trailing ratios: ROE -23.5% · ROA -14.0% · current ratio 2.16 · earnings yield -29.1% · free-cash-flow yield -1.8%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -3.27 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-23.5%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Xtant Medical Holdings (XTNT)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Xtant Medical Holdings compare with its peers?

Short answer

Xtant Medical Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Electromed, Inc. (ELMD) Same industry, near in market value$22.98 Nov 20, 2026$188M88 5-pillar Nov 22, 2026
Medtronic plc (MDT) Named competitor$99.94 Nov 20, 2026$128B82 5-pillar Nov 22, 2026
Stryker Corporation (SYK) Named competitor$310.00 Nov 20, 2026$118B81 5-pillar Nov 22, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Named competitor$101.10 Nov 20, 2026$19.1B80 5-pillar Nov 22, 2026
Boston Scientific Corporation (BSX) Named competitor$41.98 Nov 20, 2026$60.9B77 5-pillar Nov 22, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.23 Nov 20, 2026$177M72 5-pillar Nov 22, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.46 Nov 20, 2026$54.8M43 5-pillar Nov 22, 2026
Solana Company (HSDT) Same industry, near in market value$1.49 Nov 20, 2026$93.7M43 5-pillar Nov 22, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$2.93 Nov 20, 2026$87.6M41 5-pillar Nov 22, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.08 Nov 20, 2026$31.5M38 5-pillar Nov 22, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.30 Nov 20, 2026$138M37 5-pillar Nov 22, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.07 Nov 20, 2026$247M36 5-pillar Nov 22, 2026
Xtant Medical Holdings (XTNT) — this page$0.21$29.5M25

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$1.00 – $1.00
Last captured analyst target (expired, captured Nov 18, 2026)
$1.00
Last captured median analyst target (expired, captured Nov 18, 2026)
$1.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held XTNT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported XTNT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: XTNT Stock

These answers are editorial: 1 of these 9 answers is drawn from the XTNT research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for XTNT?

XTNT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Xtant Medical Holdings, Inc. specializes in regenerative medicine products and medical devices for orthopedic and neurological surgeons.

Is XTNT a good stock to buy?

Stock Expert AI does not rate XTNT buy, sell or hold. Xtant Medical Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the XTNT stock price today?

The last price recorded for Xtant Medical Holdings, Inc. (XTNT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the XTNT price target?

The last analyst consensus price target we captured for Xtant Medical Holdings, Inc. (XTNT), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What are the main risks for XTNT?

Xtant Medical Holdings, Inc. faces several risks, including regulatory challenges that could delay product approvals, intense competition from established medical device companies, and market fluctuations that may impact healthcare spending.

What are the key factors to evaluate for XTNT?

Xtant Medical Holdings, Inc. (XTNT) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. This trend is expected to drive growth in the orthopedic and neurological markets, aligning with Xtant's product offerings. Not financial advice.

How frequently does XTNT data refresh on this page?

XTNT's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven XTNT's recent stock price performance?

Xtant Medical Holdings, Inc. (XTNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio with unique biomaterials. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider XTNT overvalued or undervalued right now?

The trailing P/E of Xtant Medical Holdings, Inc. (XTNT) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.